AVARA PHARMACEUTICALS AT THE 2024 CPHI TRADE SHOW IN MILAN
FOR IMMEDIATE RELEASE
October 11, 2024 – Milan, Italy Avara Pharmaceuticals (Avara), an affiliate of American Industrial Acquisition Corporation (AIAC), exhibited at CPHI, the premier global tradeshow of the global pharmaceutical industry from October 7-11, 2024. CPHI 2024 took place at the Fiera Milano in Milan, Italy, over the span of three days, bringing together more than 45,000 attendees and featuring over 1,800 exhibitors. The event covered 1.3 million square feet of space across 13 halls, one of the largest global gatherings of pharmaceutical professionals.
Major pharmaceutical companies, including Pfizer, Novartis, AstraZeneca, Roche, Sanofi, Merck, and Bayer, were prominent exhibitors, showcasing the latest innovations in drug development, delivery systems, biologics, and manufacturing technologies. In addition to these industry giants, the event also highlighted specialized service providers, emerging startups, and contract manufacturing organizations (CMOs) such as Avara, offering a comprehensive look at the pharmaceutical supply chain.
The event featured educational panels and keynote sessions led by industry experts, with a focus on the most pressing challenges and trends in pharma, such as AI-driven drug development, sustainability, supply chain resilience, and regulatory shifts. The Innovation Gallery and Start-Up Hub provided a glimpse into the future of the industry, while discussions on green chemistry and regulatory flexibility underscored the importance of sustainability in pharmaceutical development.
At CPHI, AIAC and Avara greeted Avara’s major clients, as well as new prospective customers, discussing on going and new programs for both oral solid dose and injectibles production. Avara sponsored receptions and dinners for its clients, suppliers, colleagues and friends at the Milan Marriott Hotel, and offered tours of its extensive manufacturing campus in Liscate, a suburb of Milan.
Amit Arora, AIAC Managing Director and CEO of Avara commented “This year’s CPHI was abuzz with activity, reflecting the post-Covid dynamism and the accelerated R&D cycle offered by innovations in AI which drive advances in drug discovery, and regulatory changes.” L. M. Levie, Chairman of AIAC and Avara and Founding Trustee of the Pharma and BioPharma Outsourcing Association, the leading trade group for the pharmaceutical contract manufacturing industry, noted “The record attendance of both exhibitors and attendees amply demonstrates that this is an exciting time for our industry. We are intensely proud to exhibit at CPHI and greet our customers, who represent the largest pharmaceutical firms in the world.”
About CPHI
History of the CPHI Trade Show
CPhI (Convention on Pharmaceutical Ingredients) started in 1990 as a small, Europe-focused event aimed at bringing together key players in the pharmaceutical industry to discuss innovations, trends, and opportunities. Initially held in one European city, it quickly grew into one of the largest and most influential global platforms for pharmaceutical professionals, encompassing multiple regions and sectors within the pharmaceutical supply chain.
Over the years, the event, organized by Informa Markets, evolved beyond being a marketplace for ingredient suppliers. It became a full-scale conference, offering critical insights into industry regulations, market trends, and technological advancements. Additional segments were introduced to the event, such as finished dosage formulations (FDF), packaging (InnoPack), contract manufacturing (ICSE), machinery (P-MEC), and biotechnology, which helped shape CPhI into the comprehensive global trade event it eventually became.
With the rise of pharmaceutical hubs in Asia, CPHI expanded into China in 2001, followed by India, Japan, and Southeast Asia, solidifying its global reach. The flagship event, CPhI WorldWide, continued to be held annually in rotating European cities such as Madrid, Paris, Frankfurt, and Milan.
The CPHI Trade Show in 2024
The 2024 edition of CPHI took place at Fira de Barcelona, Spain, from October 8-10, 2024. The venue, located in the heart of Barcelona, provided state-of-the-art facilities with over 240,000 square meters of exhibition space, making it one of the largest venues in Europe.
Physical Size and Layout
CPHI 2024 spanned the entire exhibition area at Fira de Barcelona, with several thematic halls dedicated to various segments of the pharmaceutical industry:
CPHI: Focused on pharmaceutical ingredients.
ICSE: Highlighted outsourcing solutions such as contract manufacturing.
InnoPack: Concentrated on pharmaceutical packaging.
P-MEC: Showcased machinery, technology, and equipment.
BioProduction: Centered around biotechnology and biomanufacturing.
The floor plan was designed to optimize networking, featuring zones for business meetings, VIP lounges, innovation hubs, and educational workshops. A startup park for new companies, an innovation gallery showcasing breakthroughs, and dedicated areas for educational sessions were also included.
Attendees and Exhibitors
CPHI 2024 attracted over 45,000 attendees from more than 165 countries, making it a hub for global networking. Attendees included top pharmaceutical executives, researchers, regulators, industry analysts, venture capitalists, and supply chain professionals.
More than 2,500 companies exhibited at the event, ranging from industry giants like Pfizer, Novartis, AstraZeneca, and Merck to smaller firms specializing in advanced technologies, contract manufacturing, and pharmaceutical packaging. Thousands of booths showcased products ranging from active pharmaceutical ingredients (APIs) to biotechnologies, research and development services, and manufacturing equipment.
Volume of Commerce
CPHI WorldWide 2024 facilitated significant business transactions, with over €100 billion in deals and collaborations initiated or finalized during the event. Pharmaceutical companies attended not just to showcase their products but to engage in high-stakes negotiations, secure contracts, and forge alliances that impacted global supply chains.
Highlights of CPHI 2024
Sustainability Focus: The event had a strong emphasis on sustainability, with showcases of green manufacturing processes, eco-friendly packaging, and innovations aimed at reducing the pharmaceutical industry’s carbon footprint.
Digital Health and AI: A dedicated section focused on digital health innovations, particularly in AI-driven therapeutics, telemedicine, and digital health solutions.
Regulatory and Policy Forums: CPhI 2024 hosted panels and workshops addressing evolving regulatory landscapes, especially the European Union’s pharmaceutical strategy, which aimed to build a stronger and more resilient drug supply system.
Location: Milan Rho Fiera
This year's CPhI took place at the Milan Rho Fiera, one of Italy's largest and most significant exhibition centers. Spanning over 345,000 square meters, the Rho Fiera offers state-of-the-art facilities, making it the ideal venue for massive international events. As one of the pharmaceutical industry's most important global gatherings, CPhI brought together industry leaders, innovators, and professionals to exchange ideas, explore partnerships, and showcase the latest advancements in pharma technology. Its strategic location, with easy access to Milan's public transportation and major highways, provided convenience for attendees from all over the world.
For further information, please see:
About American Industrial Acquisition Corporation
American Industrial Acquisition Corporation (AIAC) is a diversified industrial group with manufacturing and distribution sites in 24 countries in North America, Europe, and Asia. AIAC has acquired and grown non-core subsidiaries and divisions of Boeing, Siemens, Lockheed Martin, Northrop Grumman, Raytheon, Johnson Controls, Merck, Pfizer, Astellas, Visteon, Carlyle, Ahlstrom, Tolko, Groupe Suez, Groupe Rexel, and many other leading multinational corporations.
AIAC companies serve companies and governmental entities worldwide in all major sectors, including aviation, space, defense, automotive, truck, rail, marine, petrochemical, solar, nuclear, food, confectionary, beverage, civil engineering and infrastructure, commercial construction, mining, dredging, disaster relief, education, medical devices, and pharmaceuticals. AIAC companies manufacture materials, components, assemblies, packaging, equipment, and finished products. In addition, AIAC companies are exclusive, authorized distributors of leading branded industrial and consumer products throughout Southeast Asia, Australia, and New Zealand. AIAC is a leading manufacturer of building, street, and highway signage in Europe, signage and illumination structures in North America, and a distributor of electrical products throughout France.
Of note, AIAC purchased Boeing Canada in 2005 and has produced over 10,000 unique components for every Boeing jet plane ever since, reliably serving Boeing from manufacturing facilities in North America. A leader in ultra-high precision jet engine component manufacturing, AIAC companies produce 2,200 fan blades and blisks for each jet engine produced by GE, Pratt & Whitney, Rolls Royce, and Honeywell. AIAC companies produce the critical automotive wire and cable for Tesla, GM, Ford, Chrysler- Fiat, Toyota, and Nissan. In connection with its kraft paper manufacturing interests in Canada and the US, AIAC controls and sustainably manages 22 million acres of Manitoba, Canada forestland, an area equivalent in size to the nation of Hungary.
AIAC companies actively support exploration into outer space, manufacturing critical components for launching and propelling spacecraft and satellites. AIAC customers in this sector include NASA, the European Space Agency, SpaceX, Blue Origin, and Boeing. AIAC companies also lead in the design and manufacture of undersea umbilical cables for worldwide oceanographic research.
Another AIAC affiliate, located in Germany, designs, manufactures and distributes high performance emergency portable power generators required during natural disasters, including extreme climate events worldwide. Clients include government agencies and the International Red Cross.
For further information, please see:
About AIAC Philanthropy
AIAC and the AIAC Foundation support a wide range of nonprofit, nonsectarian, bipartisan organizations which promote international conflict resolution, disaster relief, economic development, environmental sustainability, and exploration. The exploration-focused nonprofit organizations which they actively support include the Explorers Club, the National Geographic Society, the Royal Geographical Society, the American Museum of Natural History and the Hayden Planetarium, the Victoria & Albert Museum, the National Air and Space Museum, the National Space Society, and the United States Space Foundation.
In recent months, AIAC Companies have proudly served as a corporate sponsor of Hubert Sagniere’s historic circumnavigation of the earth in a single-engine plane (www.flightaroundtheglobe.com).
AIAC’s other beneficiaries include the Appeal of the Nobel Peace Laureates Foundation Inc., the Asia Society, the Atlantic Council, the Bill and Melinda Gates Foundation - Gates Philanthropy Partners, the Bretton Woods Committee, the Carnegie Endowment for International Peace, the Carter Center, the Council on Foreign Relations, the Economic Club of New York, the Foreign Policy Association, the Institut Française des Relations Internationales, the International Committee of the Red Cross, the International Crisis Group, the International Rescue Committee, the Japan Society, the JFK School of Government of Harvard University, the Peterson Institute for International Economics, the Richardson Center for Global Engagement, the Royal Institute of International Affairs (Chatham House), the Sierra Club, and the Trilateral Commission.
For further information, see:
https://www.aiac.com/our-values
About Avara Pharmaceutical Services
Avara Pharmaceutical Services is a global leader in contract manufacturing for pharmaceutical and biotechnology companies. With campuses in Arecibo, Puerto Rico, Norman, Oklahoma, and Liscate, Italy, Avara serves 40 countries, producing a wide range of critical medications, including oral solid dose and injectable pharmaceuticals.
During the Covid-19 pandemic, Avara played a key role in manufacturing essential treatments. In 2021, Avara Norman produced the active pharmaceutical ingredients for Remdesivir, a the leading Covid-19 treatment. Avara Liscate manufactured Nimbex for AbbVie from 2020 to 2022 and Adrenaline for Pfizer from 2020 to 2024, both vital respiratory drugs for Covid-19 patients.
Avara’s state-of-the-art facilities ensure compliance with global regulatory standards and enable efficient production processes. Committed to sustainability, Avara invests in advanced manufacturing techniques and environmental initiatives. Trusted by clients such as Aspen, AbbVie, Genentech-Roche, Merck, Pfizer, and others, Avara tailors its services to meet unique client needs.
For further information, please see:
Media Contact:
Isabel Carro-Toro, Vice President
American Industrial Acquisition Corporation
+34 689 295 827 (Spain)
+ 1 787 244 3175 (USA)
icarro-toro@aiac.com
